General Information of Drug (ID: DMZ0TDL)

Drug Name
X-387 Drug Info
Synonyms MTOR inhibitors (cancer), Shanghai Institute of Materia Medica
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Investigative [1]
Cross-matching ID
TTD Drug ID
DMZ0TDL

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sirolimus DMGW1ID Advanced cancer 2A00-2F9Z Approved [2]
Temsirolimus DMS104F Renal cell carcinoma 2C90 Approved [3]
PF-04449913 DMSB068 Chronic myelomonocytic leukaemia 2A40 Approved [4]
Everolimus DM8X2EH Advanced cancer 2A00-2F9Z Approved [5]
Novolimus DM6ZPLQ Artery stenosis BD52 Approved [1]
Zotarolimus DMRMCXW Solid tumour/cancer 2A00-2F9Z Approved [6]
Ridaforolimus DMLHEU7 Sarcoma 2A60-2C35 Phase 3 [7]
AZD2014 DMOEARH Solid tumour/cancer 2A00-2F9Z Phase 2 [8]
MM-141 DM2RJ4D Pancreatic cancer 2C10 Phase 2 [9]
PQR309 DMMCYZ8 Squamous head and neck cell carcinom 2D60.0 Phase 2 [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Serine/threonine-protein kinase mTOR (mTOR) TTCJG29 MTOR_HUMAN Inhibitor [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
2 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
3 Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9.
6 Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep. 2008 Jun;25(3):475-516.
7 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
8 Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)